Disclosures for "Cognitive and Behavioral Effects of Adjunctive Brivaracetam in Children and Adolescents with Focal Seizures: Final Data From an Open-label Follow-up Trial")
-
Dr. Elshoff has nothing to disclose.
-
Ms. Fleyshman has nothing to disclose.
-
The institution of Mrs. De la Loge has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for IPSEN. The institution of Mrs. De la Loge has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for UCB.
-
Dr. Dickson has received personal compensation for serving as an employee of UCB.
-
Dr. Reichel has received personal compensation for serving as an employee of UCB Pharma. Dr. Reichel has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for UCB Biosciences. Dr. Reichel has received stock or an ownership interest from UCB Pharma.
-
Dr. Floricel has received personal compensation for serving as an employee of UCB Biosciences GmbH. Dr. Floricel has received stock or an ownership interest from UCB Biosciences GmbH.
-
Dr. SMEYERS has nothing to disclose.